Ascelia Pharma - What happened during Q1?

You can already now sign up for the event and send in your questions. You don’t have to participate live to send in questions for the event.

Meet and ask questions to Deputy CEO Julie Waras Brogren from Ascelia Pharma on 21 May 2024 at 1:00 PM when she gives investors an update on Q1 2024.

After the closing of Q1, Ascelia Pharma confirmed that SPARKLE image reading has been completed and expects headline results in first half of May 2024. Furthermore, the company announced that they have exercised the 2nd tranche of loan facility with Formue Nord Fokus A/S.

Ascelia Pharma is a biotech company focused on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Orviglance® (Mangoral) and Oncoral – in clinical development. Ascelia Pharma has its global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE)

Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement./ Claus Thestrup 13.24 PM 23-04-2024.